Oregon Health & Science University is a public university in Oregon with a main campus, including two hospitals, in Portland. It was formed in 1974 as the University of Oregon Health science Center, combining state dentistry, medicine, and nursing programs into a single center Wikipedia.
Corless C.L.,Oregon Health And Science University
Modern Pathology | Year: 2014
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the GI tract, arising from the interstitial cells of Cajal, primarily in the stomach and small intestine. They manifest a wide range of morphologies, from spindle cell to epithelioid, but are immunopositive for KIT (CD117) and/or DOG1 in essentially all cases. Although most tumors are localized at presentation, up to half will recur in the abdomen or spread to the liver. The growth of most GISTs is driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT (75% of cases) or PDGFRA (10%). Treatment with tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib is effective in controlling unresectable disease; however, drug resistance caused by secondary KIT or PDGFRA mutations eventually develops in 90% of cases. Adjuvant therapy with imatinib is commonly used to reduce the likelihood of disease recurrence after primary surgery, and for this reason assessing the prognosis of newly resected tumors is one of the most important roles for pathologists. Approximately 15% of GISTs are negative for mutations in KIT and PDGFRA. Recent studies of these so-called wild-type GISTs have uncovered a number of other oncogenic drivers, including mutations in neurofibromatosis type I, RAS genes, BRAF, and subunits of the succinate dehydrogenase complex. Routine genotyping is strongly recommended for optimal management of GISTs, as the type and dose of TKI used for treatment is dependent on the mutation identified. © 2014 USCAP, Inc.
LaFranchi S.H.,Oregon Health And Science University
Journal of Clinical Endocrinology and Metabolism | Year: 2011
Congenital hypothyroidism, occurring in 1:3000 newborns, is one of the most common preventable causes of mental retardation. Neurodevelopmental outcome is inversely related to the age of diagnosis and treatment. Infants detected through newborn screening programs and started on L-T 4 in the first few weeks of life have a normal or near-normal neurodevelopmental outcome.Therecommendedstarting dose of L-T 4 (10-15 μg/kg · d) is higher on a weight basis than the dose for children and adults. Tailoring the starting L-T 4 dose to the severity of the hypothyroidism will normalize serum T 4 and TSH as rapidly as possible. It is important to obtain confirmatory serum thyroid function tests before treatment is started. Further diagnostic studies, such as radionuclide uptake and scan and ultrasonography, may be performed to determine the underlying cause of hypothyroidism. Because results from these tests generally do not alter the initial treatment decision, however, these diagnostic studies are rarely indicated. The developing brain has a critical dependence on thyroid hormone for the first 2-3 yr of life; thus, monitoring occurs at more frequent intervals than in older children and adults. Serum free T 4 and TSH should be checked at intervals frequent enough to ensure timely adjustment of L-T 4 dosing and to keep serum free T4 and TSH levels in target ranges. Given the success of early detection and treatment of neonates with congenital hypothyroidism, a public health mandate should be to develop similar programs for the 75% of babies worldwide who are born in areas without newborn screening programs. Copyright © 2011 by The Endocrine Society.
Sack R.L.,Oregon Health And Science University
New England Journal of Medicine | Year: 2010
A 55-year-old physician is planning a trip from Los Angeles to London to attend a scientific conference. His previous trip to Europe was complicated by sleepiness during meetings and difficulty falling asleep and remaining asleep at night. He wants to know what he can do to avoid jet lag. What would you advise? Copyright © 2010 Massachusetts Medical Society.
Ferracane J.L.,Oregon Health And Science University
Dental Materials | Year: 2011
Objectives: The objective is to review the current state of the art of dental composite materials. Methods: An outline of the most important aspects of dental composites was created, and a subsequent literature search for articles related to their formulation, properties and clinical considerations was conducted using PubMed followed by hand searching citations from relevant articles. Results: The current state of the art of dental composites includes a wide variety of materials with a broad range of mechanical properties, handling characteristics, and esthetic possibilities. This highly competitive market continues to evolve, with the major emphasis in the past being to produce materials with adequate strength, and high wear resistance and polishability retention. The more recent research and development efforts have addressed the issue of polymerization shrinkage and its accompanying stress, which may have a deleterious effect on the composite/tooth interfacial bond. Current efforts are focused on the delivery of materials with potentially therapeutic benefits and self-adhesive properties, the latter leading to truly simplified placement in the mouth. Significance: There is no one ideal material available to the clinician, but the commercial materials that comprise the current armamentarium are of high quality and when used appropriately, have proven to deliver excellent clinical outcomes of adequate longevity. © 2010 Academy of Dental Materials.
Kamimae-Lanning A.N.,Oregon Health And Science University
Blood | Year: 2013
Hematopoietic failure is the predominant clinical manifestation of Fanconi anemia (FA), a rare, recessively inherited disorder. Mutations in 1 of 15 genes that coordinately function in a complex pathway to maintain DNA integrity also predispose patients to constitutional defects in growth and development. The hematologic manifestations have been considered to reflect the progressive loss of stem cells from the postnatal bone marrow microenvironment. Ethical concerns preclude the study of human hematopoiesis in utero. We report significant late gestational lethality and profound quantitative and qualitative deficiencies in the murine Fancc(-/-) fetal liver hematopoietic stem and progenitor cell pool. Fancc(-/-) fetal liver hematopoietic stem and progenitor cells revealed a significant loss of quiescence and decline in serial repopulating capacity, but no substantial difference in apoptosis or levels of reactive oxygen species. Our studies suggest that compromised hematopoiesis in Fancc(-/-) animals is developmentally programmed and does not arise de novo in bone marrow.